Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill to Present at Upcoming Conferences in March

PR Newswire March 5, 2021

RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares

PR Newswire March 4, 2021

ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home Patient Monitoring to Date

PR Newswire March 2, 2021

RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares

PR Newswire March 2, 2021

RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares

PR Newswire March 1, 2021

RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

PR Newswire February 23, 2021

RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204

PR Newswire February 18, 2021

RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107

PR Newswire February 17, 2021

RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences

PR Newswire February 9, 2021

RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib

PR Newswire January 29, 2021

RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals

PR Newswire January 28, 2021

RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering

PR Newswire January 14, 2021

RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million

PR Newswire January 12, 2021

RedHill Biopharma Announces $10 Million Bought Deal Offering

PR Newswire January 11, 2021

RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D

PR Newswire January 11, 2021

RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease

PR Newswire January 6, 2021

RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

Canada NewsWire December 31, 2020

RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue

PR Newswire December 22, 2020

RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model

Canada NewsWire December 15, 2020

RedHill Biopharma Added to NASDAQ Biotechnology Index

PR Newswire December 14, 2020